{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028200","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.864397+00:00","generated_at":"2026-06-22T08:08:47.928529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cardiff Oncology Q3 cash burn $7.5M; Phase 1b/2 mCRC data show 35% ORR; ONSEMBLE trial on track for Q4 activation","bullets":["Cash, equivalents, and investments $114M as of Sep 30, 2022; projected runway into 2025.","Q3 2022 net cash used in operations $7.5M vs $5.5M in Q3 2021.","Phase 1b/2 mCRC trial: ORR 35% (n=48), mPFS 9.3 months, mDoR 11.7 months.","ONSEMBLE randomized Phase 2 trial in KRAS/NRAS-mutated mCRC activation expected Q4 2022.","Bevacizumab-naïve subgroup ORR 69% and mPFS 13.5 months vs historical ~25% and 6.9 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028200","json":"https://secwatch.observer/filing/0001628280-22-028200.json","markdown":"https://secwatch.observer/filing/0001628280-22-028200.md","text":"https://secwatch.observer/filing/0001628280-22-028200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/0001628280-22-028200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/crdf-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:08:47.928529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4305a835511722b0eede707e00e4fe948c9e32a8","claim":"Cardiff Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/0001628280-22-028200-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}